Erythropoiesis in Cancer Patients Undergoing Immunotherapy
We studied ten patients with various types of cancer who were being treated with Interleukin-2 (IL-2) and lymphokine activated killer cells (LAK). All patients developed a reticulocytopenic, normochromic, normocyti anemia. We noted some variability but no significant suppression of circulating erythroid progenitors. The levels of erythropoietin were lower than expected for the hemoglobin/hematocrit values.
We could not detect Interferon or Tumor Necrosis Factor (TNF) in the serum of these patients; however, the supernatant of LAK cells did contain Interferon and TNF which could be neutralized with appropriate antibodies.
These results suggest that the etiology of this anemia is multi-factorial. Administration of recombinant erythropoietin (Ep) may be of benefit in some of these patients.
KeywordsAplastic Anemia Lymphokine Activate Killer Erythroid Progenitor Lymphokine Activate Killer Cell Hemopoietic Progenitor
Unable to display preview. Download preview PDF.
- 6.. Banisadre, M., R.C. Ash, and J.L. Ascensao, et al. 1981. Suppression of erythropoiesis by mitogen-activated T-lymphocytes in vitro. In “Experimental Hematology Today”. S.J. Baum, G.D. Gedney, A. Kahn, eds. Karger, NY pp 151.Google Scholar
- 8.. Smith, K.A. 1980. T-cell growth factor. Immunol. Rev. 51: 337.Google Scholar
- 12.. Phillips, P.G., G. Chikappa, and P.S. Brinson. 1983. A Triple staining technique to evaluate monocyte neutrophil and eosinophil proliferation in soft agar cultures. Exp. Hematol. 11: 10.Google Scholar
- 16.. Zoumbos, N., E. Raefsky, and N. Young. 1986. Lymphokines and hematopoiesis. Prog. Hemat. 14: 201.Google Scholar